Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.


TSX:SVA - Post by User

Comment by wjon Jun 14, 2021 6:48pm
131 Views
Post# 33385952

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Common Sense should prevail

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Common Sense should prevailLook at the company history. They have been advancing their diabetes program on a shoestring couple of million dollars a year for years. Funny how they have the best human data in the field and have advanced two other therapeutic programs. With the bought deal the company now has the funds to better compete with their American peers. They are hiring more staff to advance their programs faster and stock options are part of the package to bring in quality staff and is standard in this field. In fact, options align staff with investors interests. Voting against the option plan cuts off the company at the knees. Complaining about the company raising money and gaining institutional investors does the same. It’s surprising how posts here often make suggestions that actually hurt or stifle investor interests. Or is the purpose to stimulate unwitting investors to sell so others can accumulate stock… 
<< Previous
Bullboard Posts
Next >>